{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:58:03Z","timestamp":1790578683761,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"DOI":"10.1007\/s00044-026-03625-3","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:49:31Z","timestamp":1790578171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications"],"prefix":"10.1007","author":[{"given":"Yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenpengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"3625_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3625_CR2","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31:S228\u201354. https:\/\/doi.org\/10.3350\/cmh.2024.0824.","journal-title":"Clin Mol Hepatol"},{"key":"3625_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL Clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028","journal-title":"J Hepatol"},{"key":"3625_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","volume":"154","author":"K Tzartzeva","year":"2018","unstructured":"Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706\u2013e17181. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.064","journal-title":"Gastroenterology"},{"key":"3625_CR5","doi-asserted-by":"publisher","first-page":"1410668","DOI":"10.3389\/fmed.2024.1410668","volume":"11","author":"Y Ma","year":"2024","unstructured":"Ma Y, Wang J, Xiao W, Fan X. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions. Front Med (Lausanne). 2024;11:1410668. https:\/\/doi.org\/10.3389\/fmed.2024.1410668.","journal-title":"Front Med (Lausanne)"},{"key":"3625_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2023.11.030","volume":"80","author":"BM Lehrich","year":"2024","unstructured":"Lehrich BM, Zhang J, Monga SP, Dhanasekaran R. Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma. J Hepatol. 2024;80:515\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2023.11.030","journal-title":"J Hepatol"},{"key":"3625_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2021;48:196\u2013203. https:\/\/doi.org\/10.1007\/s00259-020-04882-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3625_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4274\/mirt.galenos.2024.99705","volume":"33","author":"P Singh","year":"2024","unstructured":"Singh P, Singhal T, Parida GK, Rahman A, Agrawal K. Diagnostic performance of FAPI PET\/CT vs. 18F-FDG PET\/CT in evaluation of liver tumors: a systematic review and meta-analysis. Mol Imaging Radionucl Ther. 2024;33:77\u201389. https:\/\/doi.org\/10.4274\/mirt.galenos.2024.99705","journal-title":"Mol Imaging Radionucl Ther"},{"key":"3625_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","volume":"125","author":"M Capurro","year":"2003","unstructured":"Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89\u201397. https:\/\/doi.org\/10.1016\/S0016-5085(03)00689-9.","journal-title":"Gastroenterology"},{"key":"3625_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1309\/HCQWPWD50XHD2DW6","volume":"129","author":"D Baumhoer","year":"2008","unstructured":"Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129:899\u2013906. https:\/\/doi.org\/10.1309\/HCQWPWD50XHD2DW6.","journal-title":"Am J Clin Pathol"},{"key":"3625_CR11","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.7150\/jca.39972","volume":"11","author":"M Guo","year":"2020","unstructured":"Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma. J Cancer. 2020;11:2008\u201321. https:\/\/doi.org\/10.7150\/jca.39972","journal-title":"J Cancer"},{"key":"3625_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1053\/j.semnuclmed.2025.09.004","volume":"55","author":"L Filippi","year":"2025","unstructured":"Filippi L. Glypican-3: Novel theranostic agent for hepatocellular carcinoma. Semin Nucl Med. 2025;55:928\u201336. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.09.004","journal-title":"Semin Nucl Med"},{"key":"3625_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","volume":"29","author":"AR Devan","year":"2024","unstructured":"Devan AR, Nair B, Pradeep GK, Alexander R, Vinod BS, Nath LR, et al. The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential. Eur J Med Res. 2024;29:490. https:\/\/doi.org\/10.1186\/s40001-024-02073-2","journal-title":"Eur J Med Res"},{"key":"3625_CR14","doi-asserted-by":"publisher","first-page":"114391","DOI":"10.1016\/j.yexcr.2024.114391","volume":"444","author":"HA Tehrani","year":"2025","unstructured":"Tehrani HA, Zangi M, Fathi M, Vakili K, Hassan M, Rismani E, et al. GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target. Exp Cell Res. 2025;444:114391. https:\/\/doi.org\/10.1016\/j.yexcr.2024.114391.","journal-title":"Exp Cell Res"},{"key":"3625_CR15","doi-asserted-by":"publisher","first-page":"107671","DOI":"10.4254\/wjh.v17.i9.107671","volume":"17","author":"CS Wu","year":"2025","unstructured":"Wu CS, Lee TY, Chao HW. Targeting glypican-3 as a new frontier in liver cancer therapy. World J Hepatol. 2025;17:107671. https:\/\/doi.org\/10.4254\/wjh.v17.i9.107671.","journal-title":"World J Hepatol"},{"key":"3625_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13550-026-01454-4","volume":"16","author":"Y Sun","year":"2026","unstructured":"Sun Y, Qiu L. Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms. EJNMMI Res. 2026;16:112. https:\/\/doi.org\/10.1186\/s13550-026-01454-4.","journal-title":"EJNMMI Res"},{"key":"3625_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-026-01058-z","author":"N Li","year":"2026","unstructured":"Li N, Li S, Cao P, Tang M, Zhang J, Zhang W, et al. Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies. Cancer Gene Ther. 2026;33:1014\u20131023. https:\/\/doi.org\/10.1038\/s41417-026-01058-z","journal-title":"Cancer Gene Ther"},{"key":"3625_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","volume":"65","author":"GK Abou-Alfa","year":"2016","unstructured":"Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016;65:289\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.004.","journal-title":"J Hepatol"},{"key":"3625_CR19","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","volume":"18","author":"Y Sawada","year":"2012","unstructured":"Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res. 2012;18:3686\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3044.","journal-title":"Clin Cancer Res"},{"key":"3625_CR20","doi-asserted-by":"publisher","first-page":"e1346764","DOI":"10.1080\/2162402X.2017.1346764","volume":"6","author":"N Tsuchiya","year":"2017","unstructured":"Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, et al. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology. 2017;6:e1346764. https:\/\/doi.org\/10.1080\/2162402X.2017.1346764.","journal-title":"Oncoimmunology"},{"key":"3625_CR21","doi-asserted-by":"publisher","first-page":"e1129483","DOI":"10.1080\/2162402X.2015.1129483","volume":"5","author":"Y Sawada","year":"2016","unstructured":"Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5:e1129483. https:\/\/doi.org\/10.1080\/2162402X.2015.1129483.","journal-title":"Oncoimmunology"},{"key":"3625_CR22","doi-asserted-by":"publisher","first-page":"824208","DOI":"10.3389\/fonc.2022.824208","volume":"12","author":"X Zheng","year":"2022","unstructured":"Zheng X, Liu X, Lei Y, Wang G, Liu M. Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma. Front Oncol. 2022;12:824208. https:\/\/doi.org\/10.3389\/fonc.2022.824208","journal-title":"Front Oncol"},{"key":"3625_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/cells14100726","volume":"14","author":"Q Piao","year":"2025","unstructured":"Piao Q, Bian X, Zhao Q, Sun L. Unraveling glypican-3: from structural to pathophysiological roles and mechanisms-an integrative perspective. Cells. 2025;14:726. https:\/\/doi.org\/10.3390\/cells14100726","journal-title":"Cells"},{"key":"3625_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.31083\/j.fbl2907268","volume":"29","author":"A Tojjari","year":"2024","unstructured":"Tojjari A, Hafez AH, Saeed A, Singh M, Saeed A. Exploring glypican-3 as a molecular target in hepatocellular carcinoma: perspectives on diagnosis and precision immunotherapy strategies. Front Biosci (Landmark Ed). 2024;29:268. https:\/\/doi.org\/10.31083\/j.fbl2907268","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3625_CR25","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1016\/j.cell.2022.09.025","volume":"185","author":"O Akkermans","year":"2022","unstructured":"Akkermans O, Delloye-Bourgeois C, Peregrina C, Carrasquero-Ordaz M, Kokolaki M, Berbeira-Santana M, et al. GPC3-Unc5 receptor complex structure and role in cell migration. Cell. 2022;185:3931\u2013e394926. https:\/\/doi.org\/10.1016\/j.cell.2022.09.025.","journal-title":"Cell"},{"key":"3625_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.26996","volume":"60","author":"W Gao","year":"2014","unstructured":"Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology. 2014;60:576\u201387. https:\/\/doi.org\/10.1002\/hep.26996.","journal-title":"Hepatology"},{"key":"3625_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3389\/fonc.2019.00708","volume":"9","author":"A Kolluri","year":"2019","unstructured":"Kolluri A, Ho M. The role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer. Front Oncol. 2019;9:708. https:\/\/doi.org\/10.3389\/fonc.2019.00708","journal-title":"Front Oncol"},{"key":"3625_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/jcb.24404","volume":"114","author":"HL Miao","year":"2013","unstructured":"Miao HL, Pan ZJ, Lei CJ, Wen JY, Li MY, Liu ZK, et al. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP. J Cell Biochem. 2013;114:625\u201331. https:\/\/doi.org\/10.1002\/jcb.24404.","journal-title":"J Cell Biochem"},{"key":"3625_CR29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.devcel.2008.03.006","volume":"14","author":"MI Capurro","year":"2008","unstructured":"Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J. Glypican-3 inhibits hedgehog signaling during development by competing with patched for hedgehog binding. Dev Cell. 2008;14:700\u201311. https:\/\/doi.org\/10.1016\/j.devcel.2008.03.006","journal-title":"Dev Cell"},{"key":"3625_CR30","doi-asserted-by":"publisher","first-page":"E1083","DOI":"10.1073\/pnas.1217868110","volume":"110","author":"M Feng","year":"2013","unstructured":"Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2013;110:E1083\u201391. https:\/\/doi.org\/10.1073\/pnas.1217868110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3625_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2967\/jnumed.123.266766","volume":"65","author":"F Lin","year":"2024","unstructured":"Lin F, Clift R, Ehara T, Yanagida H, Horton S, Noncovich A, et al. Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma. J Nucl Med. 2024;65:586\u201392. https:\/\/doi.org\/10.2967\/jnumed.123.266766","journal-title":"J Nucl Med"},{"issue":"8 Suppl 2","key":"3625_CR32","doi-asserted-by":"publisher","first-page":"ND09","DOI":"10.1158\/1538-7445.AM2025-ND09","volume":"85","author":"J Karlsson","year":"2025","unstructured":"Karlsson J, Siegel F, Moen I, Scholz A, Mobergslien A, Suurs F, et al. Abstract ND09: BAY 3547926: novel targeted radionuclide therapy for hepatocellular carcinoma. Cancer Res. 2025;85(8 Suppl 2):ND09. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-ND09","journal-title":"Cancer Res"},{"key":"3625_CR33","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.1038\/ncomms7536","volume":"6","author":"W Gao","year":"2015","unstructured":"Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015;6:6536. https:\/\/doi.org\/10.1038\/ncomms7536.","journal-title":"Nat Commun"},{"key":"3625_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.14218\/JCTH.2025.00099","volume":"13","author":"J Zhang","year":"2025","unstructured":"Zhang J, Li R, Tan X, Wang C. Targeting glypican-3 for liver cancer therapy: clinical applications and detection methods. J Clin Transl Hepatol. 2025;13:665\u201381. https:\/\/doi.org\/10.14218\/JCTH.2025.00099","journal-title":"J Clin Transl Hepatol"},{"key":"3625_CR35","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1158\/1078-0432.CCR-25-2587","volume":"31","author":"S Fayn","year":"2025","unstructured":"Fayn S, Lee W, Basuli F, Shi J, Makala H, Chung JY, et al. Diagnosis and treatment response monitoring of liver cancer using glypican-3-targeted single-domain antibody PET. Clin Cancer Res. 2025;31:5237\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2587","journal-title":"Clin Cancer Res"},{"key":"3625_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1158\/1078-0432.CCR-25-1856","volume":"32","author":"Z Lin","year":"2026","unstructured":"Lin Z, Li M, Pan Z, Hu W, Feng Y, Zhang X, et al. Glypican-3-targeted PET imaging for precise diagnosis of hepatocellular carcinoma: From bench to bedside. Clin Cancer Res. 2026;32:550\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1856","journal-title":"Clin Cancer Res"},{"key":"3625_CR37","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","volume":"100","author":"H Shirakawa","year":"2009","unstructured":"Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100:1403\u20137. https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01206.x.","journal-title":"Cancer Sci"},{"key":"3625_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00535-013-0793-2","volume":"49","author":"IP Chen","year":"2014","unstructured":"Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol. 2014;49:117\u201325. https:\/\/doi.org\/10.1007\/s00535-013-0793-2.","journal-title":"J Gastroenterol"},{"key":"3625_CR39","doi-asserted-by":"publisher","first-page":"eaal4291","DOI":"10.1126\/scitranslmed.aal4291","volume":"9","author":"T Ishiguro","year":"2017","unstructured":"Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, et al. An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. 2017;9:eaal4291. https:\/\/doi.org\/10.1126\/scitranslmed.aal4291.","journal-title":"Sci Transl Med"},{"key":"3625_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11307-019-01356-z","volume":"22","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, et al. Radiofluorinated GPC3-binding peptides for PET imaging of hepatocellular carcinoma. Mol Imaging Biol. 2020;22:134\u201343. https:\/\/doi.org\/10.1007\/s11307-019-01356-z","journal-title":"Mol Imaging Biol"},{"key":"3625_CR41","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1039\/D0BM00943A","volume":"8","author":"Y Qin","year":"2020","unstructured":"Qin Y, Cheng S, Li Y, Zou S, Chen M, Zhu D, et al. The development of a glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma. Biomater Sci. 2020;8:5656\u201365. https:\/\/doi.org\/10.1039\/D0BM00943A","journal-title":"Biomater Sci"},{"key":"3625_CR42","doi-asserted-by":"publisher","first-page":"19714","DOI":"10.1021\/acs.jmedchem.5c02081","volume":"68","author":"G Chen","year":"2025","unstructured":"Chen G, Zhou G, Sun X, Cui Z, Yang H, Wang C, et al. 10P3Me: a GPC3-targeted peptide PET probe for subcutaneous and orthotopic HCC imaging. J Med Chem. 2025;68:19714\u201325. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02081","journal-title":"J Med Chem"},{"key":"3625_CR43","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.124.268147","volume":"65","author":"AJ Poot","year":"2024","unstructured":"Poot AJ, Lapa C, Weber WA, Lam MGEH, Eiber M, Dierks A, et al. [68Ga]Ga-RAYZ-8009: a glypican-3-targeted diagnostic radiopharmaceutical for hepatocellular carcinoma molecular imaging-A first-in-human case series. J Nucl Med. 2024;65:1597\u2013603. https:\/\/doi.org\/10.2967\/jnumed.124.268147","journal-title":"J Nucl Med"},{"key":"3625_CR44","doi-asserted-by":"publisher","first-page":"TPS611","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS611","volume":"44","author":"BR Mancini","year":"2026","unstructured":"Mancini BR, Osman M, Reilley M, Kankeu Fonkoua LA, Majeed U, Meyer J, et al. A phase 1\/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) in patients with glypican-3-positive (GPC3+) previously treated unresectable hepatocellular carcinoma. J Clin Oncol. 2026;44:TPS611. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.TPS611.","journal-title":"J Clin Oncol"},{"key":"3625_CR45","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"BK Jin","year":"2023","unstructured":"Jin BK, Odongo S, Radwanska M, Magez S, NANOBODIES\u00ae:. a review of diagnostic and therapeutic applications. Int J Mol Sci. 2023;24:5994. https:\/\/doi.org\/10.3390\/ijms24065994","journal-title":"Int J Mol Sci"},{"key":"3625_CR46","doi-asserted-by":"publisher","first-page":"1804038","DOI":"10.1155\/2024\/1804038","volume":"2024","author":"G Gezehagn Kussia","year":"2024","unstructured":"Gezehagn Kussia G, Tessema TS. The potential of single-chain variable fragment antibody: role in future therapeutic and diagnostic biologics. J Immunol Res. 2024;2024:1804038. https:\/\/doi.org\/10.1155\/2024\/1804038","journal-title":"J Immunol Res"},{"key":"3625_CR47","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","volume":"8","author":"KT Xenaki","year":"2017","unstructured":"Xenaki KT, Oliveira S, van Bergen PMP. Antibody or antibody fragments: Implications for molecular imaging and targeted therapy of solid tumors. Front Immunol. 2017;8:1287. https:\/\/doi.org\/10.3389\/fimmu.2017.01287","journal-title":"Front Immunol"},{"key":"3625_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2021.01.010","volume":"131","author":"W Wang","year":"2021","unstructured":"Wang W, Xu C, Wang H, Jiang C. Identification of nanobodies against hepatocellular carcinoma marker glypican-3. Mol Immunol. 2021;131:13\u201322. https:\/\/doi.org\/10.1016\/j.molimm.2021.01.010.","journal-title":"Mol Immunol"},{"key":"3625_CR49","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.2147\/IJN.S235058","volume":"15","author":"L Xia","year":"2020","unstructured":"Xia L, Teng Q, Chen Q, Zhang F. Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma. Int J Nanomed. 2020;15:2197\u2013205. https:\/\/doi.org\/10.2147\/IJN.S235058","journal-title":"Int J Nanomed"},{"key":"3625_CR50","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00259-025-07077-6","volume":"52","author":"X Long","year":"2025","unstructured":"Long X, Cheng S, Lan X, Wei W, Jiang D. Trends in nanobody radiotheranostics. Eur J Nucl Med Mol Imaging. 2025;52:2225\u201338. https:\/\/doi.org\/10.1007\/s00259-025-07077-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3625_CR51","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/hep.30949","volume":"71","author":"BD Fleming","year":"2020","unstructured":"Fleming BD, Urban DJ, Hall MD, Longerich T, Greten TF, Pastan I, et al. Engineered anti-GPC3 immunotoxin, HN3-ABD-T20, produces regression in mouse liver cancer xenografts through prolonged serum retention. Hepatology. 2020;71:1696\u2013711. https:\/\/doi.org\/10.1002\/hep.30949","journal-title":"Hepatology"},{"key":"3625_CR52","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.122.265171","volume":"64","author":"S Fayn","year":"2023","unstructured":"Fayn S, King AP, Gutsche NT, Duan Z, Buffington J, Olkowski CP, et al. Site-specifically conjugated single-domain antibody successfully identifies Glypican-3-expressing liver cancer by immuno-PET. J Nucl Med. 2023;64:1017\u201323. https:\/\/doi.org\/10.2967\/jnumed.122.265171","journal-title":"J Nucl Med"},{"key":"3625_CR53","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","volume":"2012","author":"ZA Ahmad","year":"2012","unstructured":"Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250. https:\/\/doi.org\/10.1155\/2012\/980250.","journal-title":"Clin Dev Immunol"},{"key":"3625_CR54","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.3390\/cancers14174206","volume":"14","author":"P Mu\u00f1oz-L\u00f3pez","year":"2022","unstructured":"Mu\u00f1oz-L\u00f3pez P, Ribas-Aparicio RM, Becerra-B\u00e1ez EI, Fraga-P\u00e9rez K, Flores-Mart\u00ednez LF, Mateos-Ch\u00e1vez AA, et al. Single-chain fragment variable: recent progress in cancer diagnosis and therapy. Cancers (Basel). 2022;14:4206. https:\/\/doi.org\/10.3390\/cancers14174206","journal-title":"Cancers (Basel)"},{"key":"3625_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00259-004-1664-0","volume":"32","author":"SC Chauhan","year":"2005","unstructured":"Chauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PR, et al. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging. 2005;32:264\u201373. https:\/\/doi.org\/10.1007\/s00259-004-1664-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3625_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/bioengineering10020122","volume":"10","author":"S Pirkalkhoran","year":"2023","unstructured":"Pirkalkhoran S, Grabowska WR, Kashkoli HH, Mirhassani R, Guiliano D, Dolphin C, et al. Bioengineering of antibody fragments: challenges and opportunities. Bioeng (Basel). 2023;10:122. https:\/\/doi.org\/10.3390\/bioengineering10020122","journal-title":"Bioeng (Basel)"},{"key":"3625_CR57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12934-019-1053-9","volume":"18","author":"A Sarker","year":"2019","unstructured":"Sarker A, Rathore AS, Gupta RD. Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process. Microb Cell Fact. 2019;18:5. https:\/\/doi.org\/10.1186\/s12934-019-1053-9.","journal-title":"Microb Cell Fact"},{"key":"3625_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13036-024-00418-3","volume":"18","author":"EB Go","year":"2024","unstructured":"Go EB, Lee JH, Cho JH, Kwon NH, Choi JI, Kwon I. Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation. J Biol Eng. 2024;18:23. https:\/\/doi.org\/10.1186\/s13036-024-00418-3.","journal-title":"J Biol Eng"},{"key":"3625_CR59","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2967\/jnumed.113.132118","volume":"55","author":"JG Sham","year":"2014","unstructured":"Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, et al. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med. 2014;55:799\u2013804. https:\/\/doi.org\/10.2967\/jnumed.113.132118.","journal-title":"J Nucl Med"},{"key":"3625_CR60","doi-asserted-by":"publisher","first-page":"4564707","DOI":"10.1155\/2019\/4564707","volume":"2019","author":"AD Ludwig","year":"2019","unstructured":"Ludwig AD, Labadie KP, Seo YD, Hamlin DK, Nguyen HM, Mahadev VM, et al. Yttrium-90-labeled anti-glypican 3 radioimmunotherapy halts tumor growth in an orthotopic xenograft model of hepatocellular carcinoma. J Oncol. 2019;2019:4564707. https:\/\/doi.org\/10.1155\/2019\/4564707","journal-title":"J Oncol"},{"key":"3625_CR61","doi-asserted-by":"publisher","first-page":"360","DOI":"10.2967\/jnumed.125.270814","volume":"67","author":"J Tjeertes","year":"2026","unstructured":"Tjeertes J, Dostalek M, Glaus C, Gupta V, Li D, Nestler A, et al. BANTAM-01: A multicenter, open-label, first-in-human phase 1 dose escalation and expansion study of 225Ac-GPC3 (BAY 3547926) in patients with advanced hepatocellular carcinoma. J Nucl Med. 2026;67:360\u20135. https:\/\/doi.org\/10.2967\/jnumed.125.270814","journal-title":"J Nucl Med"},{"key":"3625_CR62","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2967\/jnumed.114.145102","volume":"55","author":"JG Sham","year":"2014","unstructured":"Sham JG, Kievit FM, Grierson JR, Chiarelli PA, Miyaoka RS, Zhang M, et al. Glypican-3-targeting F(ab\u2019)2 for 89Zr PET of hepatocellular carcinoma. J Nucl Med. 2014;55:2032\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.145102.","journal-title":"J Nucl Med"},{"key":"3625_CR63","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","volume":"70","author":"Y Fu","year":"2019","unstructured":"Fu Y, Urban DJ, Nani RR, Zhang YF, Li N, Fu H, et al. Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma. Hepatology. 2019;70:563\u201376. https:\/\/doi.org\/10.1002\/hep.30326","journal-title":"Hepatology"},{"key":"3625_CR64","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.3390\/cancers16162896","volume":"16","author":"G Garaulet","year":"2024","unstructured":"Garaulet G, B\u00e1ez BB, Medrano G, Rivas-S\u00e1nchez M, S\u00e1nchez-Alonso D, Martinez-Torrecuadrada JL, et al. Radioimmunotheragnosis in cancer research. Cancers. 2024;16:2896. https:\/\/doi.org\/10.3390\/cancers16162896","journal-title":"Radioimmunotheragnosis Cancer Res Cancers (Basel)"},{"key":"3625_CR65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-018-0374-8","volume":"8","author":"JA Carrasquillo","year":"2018","unstructured":"Carrasquillo JA, O\u2019Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, Larson SM, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018;8:20. https:\/\/doi.org\/10.1186\/s13550-018-0374-8.","journal-title":"EJNMMI Res"},{"key":"3625_CR66","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00280-017-3241-9","volume":"79","author":"GK Abou-Alfa","year":"2017","unstructured":"Abou-Alfa GK, Yen CJ, Hsu CH, O\u2019Donoghue J, Beylergil V, Ruan S, et al. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol. 2017;79:421\u20139. https:\/\/doi.org\/10.1007\/s00280-017-3241-9.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3625_CR67","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","volume":"63","author":"Q Fu","year":"2023","unstructured":"Fu Q, Zheng Y, Fang W, Zhao Q, Zhao P, Liu L, et al. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine. 2023;63:102175. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102175.","journal-title":"EClinicalMedicine"},{"key":"3625_CR68","doi-asserted-by":"publisher","first-page":"963031","DOI":"10.3389\/fimmu.2022.963031","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Xing C, Jiang S, Yu K, Dai S, Kong H, et al. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. Front Immunol. 2022;13:963031. https:\/\/doi.org\/10.3389\/fimmu.2022.963031.","journal-title":"Front Immunol"},{"key":"3625_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10786-z","author":"Q Zhang","year":"2026","unstructured":"Zhang Q, Fu Q, Shen Y, Cao W, Jin G, Zhang Y, et al. GPC3-specific dnTGF\u03b2RII-armoured CAR T cells for hepatocellular carcinoma. Nature. 2026;657:495-504. https:\/\/doi.org\/10.1038\/s41586-026-10786-z","journal-title":"Nature"},{"key":"3625_CR70","doi-asserted-by":"publisher","first-page":"e001875","DOI":"10.1136\/jitc-2020-001875","volume":"9","author":"L Sun","year":"2021","unstructured":"Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, et al. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in hepatocellular carcinoma. J Immunother Cancer. 2021;9:e001875. https:\/\/doi.org\/10.1136\/jitc-2020-001875","journal-title":"J Immunother Cancer"},{"key":"3625_CR71","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00726-017-2517-z","volume":"50","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han YJ, Huang S, Wang M, Zhou WL, Li HS, et al. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids. 2018;50:309\u201320. https:\/\/doi.org\/10.1007\/s00726-017-2517-z.","journal-title":"Amino Acids"},{"key":"3625_CR72","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1021\/acs.molpharmaceut.1c00060","volume":"18","author":"H Xu","year":"2021","unstructured":"Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, et al. SPECT imaging of hepatocellular carcinoma detection by the GPC3 receptor. Mol Pharm. 2021;18:2082\u201390. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00060","journal-title":"Mol Pharm"},{"key":"3625_CR73","doi-asserted-by":"publisher","first-page":"679336","DOI":"10.3389\/fonc.2021.679336","volume":"11","author":"J Yan","year":"2021","unstructured":"Yan J, Yu X, Chen X, Liu F, Chen F, Ding N, et al. Identification of a Glypican-3 binding peptide from a phage-displayed peptide library for PET imaging of hepatocellular carcinoma. Front Oncol. 2021;11:679336. https:\/\/doi.org\/10.3389\/fonc.2021.679336","journal-title":"Front Oncol"},{"key":"3625_CR74","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1021\/acsptsci.4c00504","volume":"7","author":"Z Li","year":"2024","unstructured":"Li Z, Mo C, Li C, Wang Q, Huang S, Huang Y, et al. Gallium-68 labeled positron emission computed tomography tracer targeting glypican-3 with high contrast for hepatocellular carcinoma imaging. ACS Pharmacol Transl Sci. 2024;7:4021\u201331. https:\/\/doi.org\/10.1021\/acsptsci.4c00504","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3625_CR75","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s00259-022-05723-x","volume":"49","author":"S An","year":"2022","unstructured":"An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, et al. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022;49:2682\u201392. https:\/\/doi.org\/10.1007\/s00259-022-05723-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3625_CR76","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1016\/j.biomaterials.2014.04.089","volume":"35","author":"X Yang","year":"2014","unstructured":"Yang X, Liu H, Sun CK, Natarajan A, Hu X, Wang X, et al. Imaging of hepatocellular carcinoma patient-derived xenografts using 89Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials. 2014;35:6964\u201371. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.04.089.","journal-title":"Biomaterials"},{"key":"3625_CR77","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.3390\/cancers13163977","volume":"13","author":"A Natarajan","year":"2021","unstructured":"Natarajan A, Zhang H, Ye W, Huttad L, Tan M, Chua MS, et al. A humanized anti-GPC3 antibody for immuno-positron emission tomography imaging of orthotopic mouse model ofpatient-derived hepatocellular carcinoma xenografts. Cancers (Basel). 2021;13:3977. https:\/\/doi.org\/10.3390\/cancers13163977","journal-title":"Cancers (Basel)"},{"key":"3625_CR78","doi-asserted-by":"publisher","first-page":"e000548","DOI":"10.1136\/jitc-2020-000548","volume":"8","author":"SJ Waaijer","year":"2020","unstructured":"Waaijer SJ, Giesen D, Ishiguro T, Sano Y, Sugaya N, Schr\u00f6der CP, et al. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. J Immunother Cancer. 2020;8:e000548. https:\/\/doi.org\/10.1136\/jitc-2020-000548.","journal-title":"J Immunother Cancer"},{"key":"3625_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules26010004","volume":"26","author":"MM Bell","year":"2020","unstructured":"Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL, et al. Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma. Molecules. 2020;26:4. https:\/\/doi.org\/10.3390\/molecules26010004","journal-title":"Molecules"},{"key":"3625_CR80","doi-asserted-by":"publisher","first-page":"102907","DOI":"10.1016\/j.nano.2026.102907","volume":"72","author":"MH Yang","year":"2026","unstructured":"Yang MH, Chuang KP, Liang HR, Huang PC, Chuang SC, Ho TC, et al. Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma. Nanomedicine. 2026;72:102907. https:\/\/doi.org\/10.1016\/j.nano.2026.102907.","journal-title":"Nanomedicine"},{"key":"3625_CR81","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2967\/jnumed.121.262562","volume":"63","author":"KP Labadie","year":"2022","unstructured":"Labadie KP, Hamlin DK, Kenoyer A, Daniel SK, Utria AF, Ludwig AD, et al. Glypican-3-targeted 227Th \u03b1-therapy reduces tumor burden in an orthotopic xenograft murine model of hepatocellular carcinoma. J Nucl Med. 2022;63:1033\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.262562","journal-title":"J Nucl Med"},{"key":"3625_CR82","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26:3979\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3259","journal-title":"Clin Cancer Res"},{"key":"3625_CR83","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637:940\u20136. https:\/\/doi.org\/10.1038\/s41586-024-08261-8.","journal-title":"Nature"},{"issue":"Suppl 8","key":"3625_CR84","doi-asserted-by":"publisher","first-page":"viii234","DOI":"10.1093\/annonc\/mdy282.080","volume":"29","author":"AL Cheng","year":"2018","unstructured":"Cheng AL, Yen CJ, Okusaka T, Ikeda M, Hsu CH, Wu SY, et al. 697P: A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma. Ann Oncol. 2018;29(Suppl 8):viii234\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdy282.080.","journal-title":"Ann Oncol"},{"issue":"13 Suppl","key":"3625_CR85","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1158\/1538-7445.AM2018-2747","volume":"78","author":"M Endo","year":"2018","unstructured":"Endo M, Kinoshita Y, Adachi K, Narita Y, Amano J, Kato A, et al. Abstract 2747: anti-glypican-3 monoclonal antibody (codrituzumab\/GC33\/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res. 2018;78(13 Suppl):2747. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-2747","journal-title":"Cancer Res"},{"key":"3625_CR86","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/ijo.2014.2737","volume":"46","author":"Y Sawada","year":"2015","unstructured":"Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol. 2015;46:28\u201336. https:\/\/doi.org\/10.3892\/ijo.2014.2737.","journal-title":"Int J Oncol"},{"key":"3625_CR87","doi-asserted-by":"publisher","first-page":"2010894","DOI":"10.1080\/2162402X.2021.2010894","volume":"11","author":"L Shao","year":"2022","unstructured":"Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. Oncoimmunology. 2022;11:2010894. https:\/\/doi.org\/10.1080\/2162402X.2021.2010894.","journal-title":"Oncoimmunology"},{"key":"3625_CR88","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ymthe.2019.04.020","volume":"27","author":"X Wu","year":"2019","unstructured":"Wu X, Luo H, Shi B, Di S, Sun R, Su J, et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. Mol Ther. 2019;27:1483\u201394. https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.020","journal-title":"Mol Ther"},{"key":"3625_CR89","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s10238-024-01473-2","volume":"24","author":"S Chen","year":"2024","unstructured":"Chen S, Gong F, Liu S, Xie Y, Ye X, Lin X, et al. IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma. Clin Exp Med. 2024;24:204. https:\/\/doi.org\/10.1007\/s10238-024-01473-2.","journal-title":"Clin Exp Med"},{"key":"3625_CR90","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1158\/1535-7163.MCT-20-1025","volume":"21","author":"X Chen","year":"2022","unstructured":"Chen X, Chen Y, Liang R, Xiang L, Li J, Zhu Y, et al. Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and irinotecan is potent in suppressing tumor growth in mice. Mol Cancer Ther. 2022;21:149\u201358. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-1025","journal-title":"Mol Cancer Ther"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03625-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03625-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03625-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:49:32Z","timestamp":1790578172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03625-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":90,"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03625-3","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this manuscript, AI-assisted tools were used only for language editing, readability improvement, and formatting support. The authors independently verified the scientific content, reference selection, interpretation, and conclusions, and take full responsibility for the final manuscript.","order":1,"name":"Ethics","label":"Use of generative AI and AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}